InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (25 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
25
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Yale Catriona, Chief Development Officer. Insider active across 1 company, notably Akero Therapeutics, Inc.. Aggregated, 50 disclosures have been logged. Breakdown: 0 buy · 25 sells. Total volume traded: €4m. History available since 15 July 2021. The latest transaction was filed on 15 May 2025 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations50 total
27,227 sharesCommon StockSEC:0001193125-25-312100
27,227 sharesCommon StockSEC:0001193125-25-312100:0
47,573 sharesCommon StockSEC:0001193125-25-312100:1
10,000 shares@ US$21.103.1% of flowCommon StockSEC:0000950170-25-074708:0
9,073 shares@ US$21.102.7% of flowCommon StockSEC:0000950170-25-054893:0
10,000 shares@ US$21.103.1% of flowCommon StockSEC:0000950170-25-041458:0
614 shares@ US$44.880.4% of flowCommon StockSEC:0000950170-25-039736:0
10,000 shares@ US$21.103.3% of flowCommon StockSEC:0000950170-25-024996:0
16,849 shares@ US$0.6150.2% of flowCommon StockSEC:0000950170-25-011445:0
49,074 shares@ US$21.1016.0% of flowCommon StockSEC:0000950170-25-011444:0
24,300 shares0Common StockSEC:0000950170-24-138146:0
2,810 shares@ US$30.791.3% of flowCommon StockSEC:0000950170-24-136019:0
9,061 shares@ US$21.102.9% of flowCommon StockSEC:0000950170-24-128994:0
8,761 shares@ US$27.6943.7% of flowCommon StockSEC:0000950170-24-128994:1
300 shares@ US$28.8230.1% of flowCommon StockSEC:0000950170-24-128994:2
10,000 shares@ US$0.6150.1% of flowCommon StockSEC:0000950170-24-124230:0
4,515 shares@ US$21.101.4% of flowCommon StockSEC:0000950170-24-120231:0
14,825 shares@ US$0.6150.1% of flowCommon StockSEC:0000950170-24-115138:0
5,500 shares@ US$0.6150.0% of flowCommon StockSEC:0000950170-24-108837:0
2,485 shares@ US$0.6150.0% of flowCommon StockSEC:0000950170-24-107969:0
637 shares@ US$26.180.2% of flowCommon StockSEC:0000950170-24-106470:0
949 shares@ US$0.6150.0% of flowCommon StockSEC:0000950170-24-103977:0
8,851 shares@ US$0.6150.1% of flowCommon StockSEC:0000950170-24-101257:0
1,064 shares@ US$19.9410.3% of flowCommon StockSEC:0000950170-24-080924:0
2,825 shares@ US$22.6411.0% of flowCommon StockSEC:0000950170-24-073190:0
25 of 50 declarations
About Yale Catriona
Catriona Yale is the Chief Development Officer at Akero Therapeutics, Inc. She is responsible for product development strategy and growth initiatives for the company. Her expertise in the pharmaceutical sector enables her to lead innovative projects and contribute to the advancement of therapeutic treatments.
